Abstract
Objective. - Vascular gene transfer provides unique opportunities for novel therapies for cardiovascular disease. To define the limitations and expectations of translating preclinical strategies to clinical therapy, the kinetics and extent of vascular transgene expression must be determined. Data Sources. - Published clinical and preclinical studies of vascular gene transfer. Data Extraction. - Kinetics and extent of vascular transgene expression. Data Synthesis. - In spite of ongoing clinical studies in vascular gene transfer, data regarding the kinetics and extent of transgene expression are very limited. Conclusions. - For the efficient translation of preclinical to clinical vascular gene transfer studies, the kinetics and extent of transgene expression should be determined. Novel imaging technologies and unique clinical scenarios for obtaining tissue should be considered.
| Original language | English |
|---|---|
| Pages (from-to) | 317-319 |
| Number of pages | 3 |
| Journal | Archives of Pathology and Laboratory Medicine |
| Volume | 126 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2002 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Clinical trials in vascular gene therapy: The missing piece of the puzzle'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver